Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Verapamil sustained-release

Szekely LA, Thompson BT, Woolf A. Use of partial hquid ventilation to manage pulmonary complications of acute verapamil-sustained release poisoning. J Toxicol Chn Toxicol 1999 37(4) 475-9. [Pg.3621]

Verapamil (Table 1), the first slow channel calcium blocker synthesized to selectively inhibit the transmembrane influx of calcium ions into cells, lowers blood pressure in hypertensive patients having good organ perfusion particularly with increased renal blood flow. Sustained-release verapamil for once a day dosing is available for the treatment of hypertension. Constipation is a prominent side effect. Headache, dizziness, and edema are frequent and verapamil can sometimes cause AV conduction disturbances and AV block. Verapamil should not be used in combination with -adrenoceptor blockers because of the synergistic negative effects on heart rate and contractile force. [Pg.142]

Marvola, M., Aito, H., Pohto, P., Kannikoski, A., Nykanen, S., Kokkonen, P., Gastrointestinal transit and concomitant absorption of verapamil from a single-unit sustained-release tablet, Drug Dev. Ind. Pharm. 1987, 13, 1593-1609. [Pg.566]

Similar labeling language also in the labeling of ISOPTIN SR (Abbott) (verapamil HCl) sustained release oral tablets July 2003 and VERELAN PM capsules (Schwarz) (verapamil hydrochloride) extended-release capsules controlled-onset, March 2003. [Pg.269]

The effect of food on gastrointestinal transit and drug absorption of a multiparticular sustained release verapamil... [Pg.125]

Fig. 2—Absorption of verapamil after a single dose of a sustained release pellet formulation in six healthy volunteers. The position of the majority of pellets at each blood sampling was detected by X-rays. S, stomach I, intestine C, colon o, fasting , non-fasting. Fig. 2—Absorption of verapamil after a single dose of a sustained release pellet formulation in six healthy volunteers. The position of the majority of pellets at each blood sampling was detected by X-rays. S, stomach I, intestine C, colon o, fasting , non-fasting.
Verapamil Spheronized Pellets for Sustained Release Coating (48%)... [Pg.398]

See also Sustained Release Coating of Verapamil Pellets ... [Pg.398]

Figure 5 Chromatogram of plasma from a healthy volunteer 4 hr after the administration of 240 mg of a sustained-release formulation of racemic verapamil, where 1 = (S)-verapamil, 2 = (R)-verapamil, 3 = internal standard, 4 = (S)-norverapamil, 5 = (R)-norverapamil. [From Shibukawa and Wainer (53).]... Figure 5 Chromatogram of plasma from a healthy volunteer 4 hr after the administration of 240 mg of a sustained-release formulation of racemic verapamil, where 1 = (S)-verapamil, 2 = (R)-verapamil, 3 = internal standard, 4 = (S)-norverapamil, 5 = (R)-norverapamil. [From Shibukawa and Wainer (53).]...
Figure 4 Mean it-verapamil S-verapamil ratio observed following intravenous and oral dosing of racemic verapamil. A, After intravenous administration of a single 15 mg dose in 8 volunteers (personal communication from A. Rasymas, Univ. of Toronto, Canada). B, After oral administration of two different 120-mg immediate release formulations dosed every 8 hr to 22 normal volunteers in a crossover design study and measured at steady state over two dosing intervals (- -, test formulation u, reference formulation). C, After oral administration of two different lots of a 180-mg once daily sustained-release formulation to 48 normal volunteers in a cross-over design study and measured at steady state new manufacturing site n, reference manufacturing site). Figure 4 Mean it-verapamil S-verapamil ratio observed following intravenous and oral dosing of racemic verapamil. A, After intravenous administration of a single 15 mg dose in 8 volunteers (personal communication from A. Rasymas, Univ. of Toronto, Canada). B, After oral administration of two different 120-mg immediate release formulations dosed every 8 hr to 22 normal volunteers in a crossover design study and measured at steady state over two dosing intervals (- -, test formulation u, reference formulation). C, After oral administration of two different lots of a 180-mg once daily sustained-release formulation to 48 normal volunteers in a cross-over design study and measured at steady state new manufacturing site n, reference manufacturing site).
Our first stereospedfic bioequivalence evaluation using verapamil formulations was a pilot study conducted in 24 healthy male volunteers. The study compared the bioavailability of two sustained-release dosage forms and an immediate release formulation of racemic verapamil in a three-way cross-over study. Table 2 summarizes the results observed for verapamil. Table 3 the results for norverapamil. First, pharmacokinetic... [Pg.325]

Figure 6 Mean relationship observed between prolongation of the PR interval and verapamil concentration measured in 24 normal volunteers using a nonstereos pedfic verapamil assay. The immediate release formulation was given 80 mg every 8 hr both sustained-release formulations were given 240 mg once daily. Concentrations and PR intervals were measured at steady state. Figure 6 Mean relationship observed between prolongation of the PR interval and verapamil concentration measured in 24 normal volunteers using a nonstereos pedfic verapamil assay. The immediate release formulation was given 80 mg every 8 hr both sustained-release formulations were given 240 mg once daily. Concentrations and PR intervals were measured at steady state.
Figure 7 Stereospedfic comparison of concentration-time profiles of verapamil and norverapamil obtained from two lots of sustained-release verapamil manufactured at different manufacturing sites (—new manufacturing site —, reference manufacturing site). Sustained-release racemic verapamil was administered 240 mg once daily to the 44 normal volunteers in a cross-over design study plasma samples were collected at steady state on d s 7-8. (On days 6 and 7 verapamil was administered with food, and on day 8 it was administered while fasting.)... Figure 7 Stereospedfic comparison of concentration-time profiles of verapamil and norverapamil obtained from two lots of sustained-release verapamil manufactured at different manufacturing sites (—new manufacturing site —, reference manufacturing site). Sustained-release racemic verapamil was administered 240 mg once daily to the 44 normal volunteers in a cross-over design study plasma samples were collected at steady state on d s 7-8. (On days 6 and 7 verapamil was administered with food, and on day 8 it was administered while fasting.)...
X BLE 4 Verapamil and Norverapamil Chiral Bioequivalence Comparisons for Two Lots of Sustained-Release Racemic Verapamil Tablets Manufactured at Different Sites... [Pg.331]

Figure 8 R-verapamil S-verapamil ratio observed following a single 180-mg dose of sustained-release racemic verapamil. (The comparable relationship for the same formulation, at the same dose, but at steady state is shown as curves (C) in Fig. 3.)... Figure 8 R-verapamil S-verapamil ratio observed following a single 180-mg dose of sustained-release racemic verapamil. (The comparable relationship for the same formulation, at the same dose, but at steady state is shown as curves (C) in Fig. 3.)...
Figure 9 Pharmacodynamic relationship observed at steady state in 24 subjects for various doses of a sustained-release (once daily) verapamil formulation. The concentration measure used is the area under the S-verapamil concentration over the 24-hr dosing interval the effect measure used is the area under the PR interval curve (measured with Holter monitor) over the 24-hr dosing interval. The doses of sustained-release verapamil that resulted in each concentration-effect pair are also shown. Figure 9 Pharmacodynamic relationship observed at steady state in 24 subjects for various doses of a sustained-release (once daily) verapamil formulation. The concentration measure used is the area under the S-verapamil concentration over the 24-hr dosing interval the effect measure used is the area under the PR interval curve (measured with Holter monitor) over the 24-hr dosing interval. The doses of sustained-release verapamil that resulted in each concentration-effect pair are also shown.
Ben-Noun L. Acute asthma associated with sustained-release verapamil. Ann Pharmacother 1997 31(5) 593-5. [Pg.606]

Verapamil 40 mg t.i.d. 240 mg/day 10% 100% 100% 100% Acute renal dysfunction active metabolites accumulate particularly with sustained-release forms. NC NC Dose for GFR 10-50 ml/min... [Pg.930]

Calan SR [Searle], TM for verapamil hydrochloride in sustained-release oral caplet form. [Pg.212]

See other pages where Verapamil sustained-release is mentioned: [Pg.130]    [Pg.608]    [Pg.183]    [Pg.184]    [Pg.117]    [Pg.139]    [Pg.183]    [Pg.184]    [Pg.130]    [Pg.608]    [Pg.183]    [Pg.184]    [Pg.117]    [Pg.139]    [Pg.183]    [Pg.184]    [Pg.404]    [Pg.94]    [Pg.7]    [Pg.125]    [Pg.238]    [Pg.370]    [Pg.371]    [Pg.312]    [Pg.250]    [Pg.121]    [Pg.466]    [Pg.466]    [Pg.322]    [Pg.323]    [Pg.323]    [Pg.326]    [Pg.326]    [Pg.329]    [Pg.330]    [Pg.1093]    [Pg.3945]    [Pg.2559]    [Pg.72]   
See also in sourсe #XX -- [ Pg.208 , Pg.283 ]



SEARCH



© 2024 chempedia.info